Docetaxel 80 mg, 1 vial for intravenous infusion, Kocak Ilac, Turkey Docetaxel is used for approved cancer indications including breast cancer. International medicine delivery within 4-5 days with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.
Delivery methods
- We can ship by mail to any European country with a delivery time of 8-10 days. Only medications that do not require refrigeration possible shipping. Shipping costs are 40-50 euro, depending on the destination country.
Delivery time
- Originator medicines: 8-10 days
- Generic medicines: 8-10 days
Payment methods
- Bank transfer to the settlement account after receiving the order
indications
- Breast cancer. Taxotere ® in combination with doxorubicin and cyclophosphamide is intended for the adjuvant treatment of patients with:
- operable breast cancer with lymph node involvement
- operable breast cancer without lymph node involvement.
- For patients with resectable node-negative breast cancer, adjuvant therapy should be given if patients are eligible for chemotherapy in accordance with accepted international criteria for primary therapy of early-stage breast cancer.
- Taxotere ® in combination with doxorubicin is indicated for the treatment of patients with locally or metastatic breast cancer who have not previously received cytotoxic therapy for this disease.
- Taxotere ® as monotherapy is indicated for the treatment of patients with locally or metastatic breast cancer after ineffective cytotoxic therapy, which included an anthracycline or alkyluvalium drug.
- Taxotere ® in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer with increased expression of HER-2 by tumor cells who have not previously received chemotherapy for metastases.
- Taxotere ® in combination with capecitabine is indicated for the treatment of patients with locally or metastatic breast cancer after ineffective therapy that included an anthracycline.
- Non-small cell lung cancer. Taxotere ® is indicated for the treatment of patients with locally or metastatic non-small cell lung cancer after ineffective chemotherapy.
- Taxotere ® in combination with cisplatin is indicated for the treatment of patients with unresectable, locally or metastatic non-small cell lung cancer who have not received previous chemotherapy for the condition.
- Prostate cancer Taxotere ® in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.
- Adenocarcinoma of the stomach. Taxotere ® in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including gastroesophageal adenocarcinoma, who have not previously received chemotherapy for metastases.
- Head and neck cancer. Taxotere ® in combination with cisplatin and 5-fluorouracil
No reviews yet
